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Abstract
Background: Silver-Russell Syndrome (SRS) is a rare growth-related genetic disorder mainly characterized by
prenatal and postnatal growth failure. Although molecular causes are not clear in all cases, the most common
mechanisms involved in SRS are loss of methylation on chromosome 11p15 (≈50%) and maternal uniparental
disomy for chromosome 7 (upd(7)mat) (≈10%).
Case presentation: We present a girl with clinical suspicion of SRS (intrauterine and postnatal growth retardation,
prominent forehead, triangular face, mild psychomotor delay, transient neonatal hypoglycemia, mild hypotonia and
single umbilical artery). Methylation and copy number variations at chromosomes 11 and 7 were studied by methylation-
specific multiplex ligation-dependent probe amplification and as no alterations were found, molecular karyotyping was
performed. A deletion at 5p15.33p15.2 was identified (arr[GRCh37] 5p15.33p15.2(25942–11644643)× 1), similar to those
found in patients with Cri-du-chat Syndrome (CdCS). CdCS is a genetic disease resulting from a deletion of variable size
occurring on the short arm of chromosome 5 (5p-), whose main feature is a high-pitched mewing cry in infancy,
accompanied by multiple congenital anomalies, intellectual disability, microcephaly and facial dysmorphism.
Conclusions: The absence of some CdCS features in the current patient could be due to the fact that in her case the
critical regions responsible do not lie within the identified deletion. In fact, a literature review revealed a high degree of
concordance between the clinical manifestations of the two syndromes.
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Background
Silver-Russel Syndrome (SRS, OMIM#180860) is a rare
genetic imprinting disorder, initially described as an het-
erogeneous phenotype including intrauterine (IUGR) and
postnatal growth retardation (PNGR) without catch-up
growth, relative macrocephaly at birth, triangular face,
body asymmetry, facial dysmorphic features and severe
feeding difficulties [1, 2]. More recent case reports have
led to the inclusion of low body mass index,
hypoglycemia, motor and speech delay and psychosocial
challenges as additional features (for a review, [3]). The in-
cidence of the disease is not clear, reported estimates
varying from 1/100,000 to 30/100,000 [3, 4]. Most cases of
SRS are sporadic, with a low rate of familial cases that
have been suggested to follow an autosomal dominant
transmission pattern [5].
The wide variability of the clinical manifestations of
SRS has led to the international recommendation to use
the Netchine-Harbison SRS clinical scoring system
(NH-CSS) [6], both for determining when SRS genetic
testing should be run and when a clinical diagnosis of
SRS should be given [3]. Although studies have failed to
determine the underlying molecular mechanism in some
cases, approximately 50% of the clinically-diagnosed SRS
patients present alterations at 11p15.5, mainly hypome-
thylation at H19/IGF2:IG-DMR, while 10% of them
show maternal uniparental disomy of chromosome 7
(upd(7)mat) [3]. In addition, there have been reports of a
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single maternally-transmitted CDKN1C activating muta-
tion in five members of a four-generation family [7] and
paternal IGF2 inactivating mutations in another family
and four unrelated patients [8–10]. Further, sequence
variants of two non-imprinted genes (HMGA2 and
PLAG1) are also associated with SRS. Specifically,
HMGA2 variants have been described in one family and
two sporadic cases [11, 12] and PLAG1 mutations in a
family and in one sporadic case [11]. For the remaining
40% of SRS patients who are negative for these alter-
ations, molecular karyotyping is advised [3, 13, 14]. Two
recent reviews have compiled all the reported chromo-
somal regions involved in SRS-like cases and suggested
that the most frequently affected is 12q14, followed by
1q21, 4p16.3, 15q26, 17p13.3 and 22q11 [9, 15].
Case presentation
The CARE guidelines were followed in reporting this
case.
Case report
We present the case of a girl who is the third child of
healthy non-consanguineous parents. A prenatal ultrasound
test revealed a single umbilical artery with no other malfor-
mations. She was born at term, by vaginal delivery after in-
duction due to fetal hypomobility, with a birth weight of
2450 g (p < 1), birth length of 47 cm (p3), and cranial per-
imeter of 33 cm (p10). No perinatal diseases were detected,
except for one episode of transient neonatal hypoglycemia.
In the neonatal period, no abnormal cry was noticed. She
was monitored closely because of postnatal growth retar-
dation in the absence of familial short stature (father’s
height 180 cm, mother’s height 158 cm). At 22months of
age, she was referred for brain magnetic resonance imaging
because of neurodevelopmental delay, and Arnold Chiari
malformation type I and corpus callosum hypoplasia with
mild ventriculomegaly were identified. A peculiar face with
triangular shape was observed and height (78.5 cm, p3) and
weight (9.7 kg, p7) were still delayed. Generalized hypotonia
was still present. Surgery for Arnold Chiari I was per-
formed, and subsequently, her motor development slightly
improved. At the age of 49/12, she was referred for clinical
genetic assessment and SRS was suspected with a score of
4/6 on the NH-CSS: including IUGR, PNGR, prominent
forehead and triangular face (Fig. 1a). At this age, she had a
weight of 14.4 kg (p7), a height of 99.5 cm (p2) and a cranial
perimeter of 49 cm (p15). Phenotypically, she also pre-
sented craniofacial disproportion, wide normal set rotated
ears, a triangular face, large eyes and narrow nasal bridge
(Fig. 1a), as well as small feet and hands with quadrangular
fingertips (Fig. 1b). The 5th finger on each hand was short-
ened without clinodactyly (Fig. 1b); the great toe of each
foot was wide and she had bilateral diastasis between the
first and second toes. She also had a very smooth non-nasal
voice.
Molecular genetic studies
Genomic DNA was extracted from peripheral blood leuko-
cytes using a commercial kit, following the manufacturer’s
instructions (QiaAmp Blood Mini, Qiagen, Düren,
Germany). Dosage and methylation analyses for chromo-
somes 11 and 7 were carried out by methylation-specific
multiplex ligation-dependent probe amplification using the
ME030-C3 and ME032-A1 kits, respectively (MRC-Holland,
Amsterdam, The Netherlands) following the manufacturer’s
recommendations. No alterations in methylation or copy
number variations (CNV) were detected in either of these
regions.
Subsequently, molecular karyotyping was performed
using a 400 K microarray-based comparative genomic
hybridization (aCGH) kit (G4448A, Agilent Technologies,
Santa Clara, CA, USA). Slides were scanned on an Agilent
SureScan C Microarray scanner and analyzed with Agilent
CytoGenomics software, revealing a deletion on the short
arm of chromosome 5, specifically at 5p15.33p15.2
(arr[GRCh37] 5p15.33p15.2(25942–11644643)× 1) (Fig. 2),
Fig. 1 Clinical photograph of the patient. a: Front view of the face. Note the prominent forehead, triangular face, large eyes and narrow nasal
bridge. b: Palmar view of the hand showing the small size and quadrangular fingertips
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within the region usually associated with Cri-du-chat syn-
drome (CdCS).
Fluorescence in situ hybridization (FISH) analyses were
performed on metaphase cells and interphase nuclei using a
Vysis CSF1R/D5S23, D5S721 FISH Probe Kit to confirm the
presence of the deletion and its origin. The results showed
one green signal (5p15) and two red signals (CSF1R probe)
in the metaphases and nuclei of the index corresponding to
a deletion of the 5p15 region (Additional file 1 Figure S1A,
B), confirming the aCGH results. In accordance with the
2016 edition of the International System for Human Cytoge-
nomic Nomenclature, the patient’s karyotype can be de-
scribed as 46,XX,del(5)(p15.2).ish del(5)(p15.2)(D5S23-,
D5S721-). The FISH pattern on chromosome 5 was normal
in both parents (2G2R), confirming the de novo nature of
the deletion (Additional file 1 Figure S1C-F).
Clinical re-evaluation
A literature review showed us that there are some clin-
ical features which are common to CdCS and SRS
(Table 1). Keeping the results of this review and the gen-
etic analysis in mind, clinical re-evaluation at 5 years 6
months of age confirmed some features suggestive of
SRS (failure to thrive, retarded postnatal growth [height
104.5 cm (p4), weight 15.2 kg (p9), cranial perimeter
49.2 cm (p12)], prominent forehead) and some others of
CdCS (slightly prominent chin with micrognathia); how-
ever, she did not have lip, palatal or mouth alterations;
small hands with thin and long fingers; sandal gap de-
formity; or clinodactyly. The neurodevelopmental study
revealed that she has not achieved the milestones for her
chronological age (sitting without support and crawling
at 12 months; walking independently at 25 months; very
poor speech and verbal development with just 5–10
words at 2 years; and at the time of writing she still has
neither bowel nor bladder control, is not able to read or
write, and lacks fine motor skills). She is receiving psy-
chological and learning support at school. She also has a
high-pitched voice and dysphonia (possibly due to a de-
fect in the larynx with vocal fold atrophy).
Discussion and conclusions
Sometimes, clinical diagnosis of patients with syndromic
manifestations is challenging due to either an absence of
cardinal features or an overlap of characteristics between
different disorders or a combination of both.
It is known that CdCS (OMIM#123450) is caused by
deletions of heterogeneous size in the short arm of
chromosome 5 [16]. Even though it is considered a rare
disease, CdCS is one of the most common chromosomal
deletion syndromes with an incidence ranging from
1:15,000 [17] to 1:50,000 live births [18]. In more than
80% of cases, the deletion is found to be de novo [19]
and its extension seems to be closely related to the pre-
sence of certain phenotypic features [20].
The main clinical features at birth are: plaintive
high-pitched monochromatic cry similar to the mewing of
a cat (95.9%), which disappears after the neonatal period;
microcephaly (mean head circumference, 31.8 cm) and
low weight (mean weight, 2614 g). Other notable charac-
teristics are: rounded face (83.5%), broad nasal bridge
(87.2%), hypertelorism (81.4%), epicanthal folds (90.2%),
downslanting palpebral fissures (56.9%), low-set ears
(69.8%), micrognathia (96.7%), abnormal dermatoglyphics
(92%), hypotonia and down-turned corners of the mouth
(81.0%) [21]. CdCS patients also show severe psychomotor
and intellectual disability, high palatal arch [20], speech
delay, prenatal and postnatal growth delay, and low-set
and/or poorly formed pinnae [22].
Fig. 2 Schematic view of the short arm of chromosome 5, showing some described deletions and genes important in CdCS. The red bar at the
top shows the deletion in the patient. Garnet bars are an indication of approximate regions deleted in several different patients described in
literature, based on a recent review [35]. Some of the genes associated with the important features of CdCS are highlighted in blue
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The majority of chromosome 5p deletions are associ-
ated with CdCS, but a del(5p) karyotype does not neces-
sarily indicate CdCS [20, 23]. According to various
different mapping studies using a strategy of “phenotype
dissection”, some regions of the short arm of chromo-
some 5 have been associated with specific features which
define certain aspects of the CdCS phenotype. Based on
those studies, the critical factor responsible for the CdCS
phenotype is considered to be the deletion located at
5p15.2, as haploinsufficiency of genes in this region is
assumed to be associated with changes in facial features
and severe mental retardation, as well as general CdCS
features [19, 20, 22, 24]. Patients presenting the charac-
teristic cat-like cry, the origin of the name of the
Table 1 Clinical characteristics of Silver-Russell Syndrome (SRS) (Wakeling et al., 2017 [3]) and Cri-du-Chat Syndrome (CdCS) (Cerruti
Mainardi, 2006 [21]; D M Church et al., 1995 [20]; D M Church et al., 1997 [22]) together with features observed in our patient
IUGR IUGR IUGR
PNGR PNGR PNGR
Speech delay Speech delay Speech delay
Motor delay Motor delay Motor delay
Hypotonia Hypotonia Hypotonia
Mild intellectual delay Intellectual disability Intellectual disability
High pitched/squeaky 
voice
High pitched cry High pitched voice
Micrognathia Micrognathia Micrognathia
Low set and/or posteriorly 
rotated ears
Low set ears
Down-turned corners of the 
mouth
Down-turned corners of the 
mouth
Clinodactyly Clinodactyly (rare cases)
Hypoglycaemia Hypoglycaemia
Prominent forehead Prominent forehead
Triangular face Triangular face
Feeding difficulties 













Body asymmetry No asymmetry No asymmetry
Normal nose Broad nasal bridge with 
prominent nasal root
Normal nose
No data Abnormal dermatoglyphics No data
No palatal alteration High palatal arch No palatal alteration
No hypertelorism Hypertelorism No hypertelorism
Normal eyelids Epicanthal folds Normal eyelids
Normal eyes Downslanting palpebral 
fissures
Normal eyes
No data Small hands with thin and 
long fingers
Short fingers
No sandal gap Sandal gap in both feet Normal feet
From darkest to lightest grey, the features are highlighted as follows: common features between (1) SRS, CdCS and the patient, (2) SRS and CdCS, (3) SRS and the
patient and (4) CdCS and the patient. IUGR intrauterine growth retardation, PNGR post-natal growth retardation. Underlined features are those most specific to
each syndrome
Vado et al. BMC Medical Genomics          (2018) 11:124 Page 4 of 7
syndrome, carry a deletion that includes a region prox-
imal to 5p15.3 and distal to 5p15.2 [24, 25]. Different
genes located within this region have been proposed to
be responsible for the feature, namely, UBE2QL1/
FLJ28076 (5p15.31) and MARCH6/TEB4 (5p15.2) [26].
Surprisingly, the deletion of the patient we report en-
compasses both candidate genes, but she did not have
the classical cry, just a high-pitched voice. Coinciden-
tally, there is another CdCS case described in the litera-
ture in which the patient did not have high pitched cry
but did have a high-pitched voice. He had a 5p15.2 dele-
tion, similar to our patient, and they share other clinical
characteristics such as growth delay, slightly small chin,
hypotonia and speech delay [22].
The most distal part of 5p, the 5p15.3 band, has been
reported to be related to speech delay [27]. In that
region, more precisely at 5p15.33, studies have located
the SLC6A3 gene, which encodes an amine transporter
responsible for dopamine reuptake. Curiously, an excess
of dopamine has been associated with problems in
speech due to its major role in fine motor movements
and the fact that speech requires very accurate coordin-
ation of very diverse small muscles [28]. The patient we
describe has speech problems, probably because of a de-
fect in the in the larynx with vocal fold atrophy. Notably,
the SLC6A3 gene lies within the patient’s deletion, and
that may explain the speech problems.
In addition, intellectual disability has been associated
with a region at 5p15.2 [24], where the CTNND2 gene is
located [29]. This gene encodes a protein which plays a
critical role in neural development, particularly in the
formation and/or maintenance of dendritic spines and
synapses [30]. In the same cytogenetic band, there is an-
other region which seems to be responsible for the facial
dysmorphism [19, 22, 31]. Further, alterations in
SEMA5A (5p15.31) [32] and CDH18 (5p14.3), CDH10
(5p14.2) and CDH9 (5p14.1) [33] also disrupt normal
brain development; whereas autism spectrum and social
communication disorders have been associated with the
5p14.1 cytogenetic band [34]. Like many other cases and
as described above, our patient has intellectual disability,
not having achieved the milestones for her age. Even
though CDH9, CDH10 and CDH18 genes are supposed
to be involved in intellectual disability, they may be not
so critical because they do not lie within the region of
the patient’s deletion. On the contrary, CTNND2 and
SEMA5A are in the deleted region and in consequence
they may be responsible for this feature. On the other
hand, autism is not one of the girl’s characteristics, per-
haps due to the fact that the aforementioned region does
not lie within the deletion. The CDH9 gene is located in
the band related to autism, and hence, it could be
responsible for this feature apart from intellectual
disability.
Some of these phenotypic features are in common
with those of SRS (Table 1). In fact, the patient we de-
scribe has four out of the six cardinal characteristics [6]
of SRS and lacks other important features of CdCS (high
pitched cry, rounded face). What is more, the syndromes
share some cardinal features, making it difficult to reach
an accurate clinical diagnosis when they are present in a
patient. On the other hand, according to the recent re-
views [9, 15], ours is the first report of a patient with
SRS carrying a deletion at 5q. As suggested above, the
reason for the absence of these cardinal CdCS features
could be that the chromosomal regions involved in these
signs are not deleted in our patient. Nevertheless, as pre-
viously suggested by other authors [26], it is important
to underline the great variability in each feature as each
individual trait is not caused by alterations in a single
gene. Detailed molecular analysis of more patients with
well-established clinical features is necessary to identify
the role of the genes responsible for the CdCS.
In brief, overlapping clinical manifestations of different
disorders can lead to a misdiagnosis that could be
avoided with more detailed molecular testing. Specific-
ally, deletions at 5p should be considered in clinical SRS
patients with negative results for chromosome 11 and 7
alterations.
On the other hand, given the importance of correlating
the deleted regions at 5p and the clinical features associated
with CdCS, some chromosomal maps have been developed.
Nevertheless, more molecular karyotyping studies would
help identify precise genomic coordinates responsible for
each feature of the syndrome.
Additional file
Additional file 1: Figure S1. FISH images of the index, her father and
her mother. DX0164-I code is for the patient, DX0164-P for the father and
DX0164-M for the mother. A, C, E pictures are from interphase nuclei and
B, D, F from chromosomes in metaphase. One green signal (5p15) and
two red signals (CSF1R probe) are visible in the index, suggesting a dele-
tion of the 5p15 region. Both parents presented a normal result (2G2R)
for FISH on chromosome 5. (TIF 235 kb)
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